1. South Korea Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Inventage Lab, Inc.

Inventage Lab, Inc.

KKRX:389470
24,350.00
KRW
-750.00
(-2.99%)
-864.39EPS
524.45BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
193.13
276.31
512.06
78.31
194.48
266.14
198.54
Basic EPS, GAAP
-2,003.9
-4,678
-1,376
-1,457
-3,212
-1,854
-766
-252.17
Free Cash Flow per Basic Share
-873.35
-2,043.64
-1,634.04
-985.83
-2,243.19
-1,961.76
-2,496.97
-2,756.35
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3,531.59
2,036.33
3,228.53
3,644.3
521.75
3,241.88
4,855.07
6,655.07
Tangible Book Value per Share
-3,555.35
1,995.92
3,168.17
3,556.77
78.99
2,785.12
3,726.03
5,488.07
Basic Weighted Avg Shares
8
3
7
7
8
9
11
12
Sales/Revenue/Turnover
- -
532
1,862
3,724
658
1,783
2,939
2,473
Operating Margin (%)
- -
-1,041.27
-513.38
-292.77
-2,427.53
-1,063.62
-965.74
-1,359.73
Depreciation Expense
641
1,118
1,844
2,424
2,611
3,832
7,621
7,953
Net Income, GAAP
-16,443
-12,880
-9,271
-10,595
-26,994
-16,997
-8,458
-3,141
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-2,422.26
-497.98
-284.54
-4,101.51
-953.29
-287.82
-127.01
Working Capital
-32,989
10,716
19,770
22,669
-2,662
38,183
20,235
78,879
LT Debt
3,910
4,095
2,758
1,730
6,236
13,425
7,277
22,689
Total Equity
-28,978
16,709
26,491
30,435
4,411
32,565
80,851
111,082
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-42.92
-37.22
-154.94
-91.93
-17.44
-4.84

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13,205
12,409
12,112
LT Borrowings
2,342
17,552
18,548
LT Finance Leases
4,935
4,543
4,141
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
1,117,950
869,664
524,454

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
40,028
141,288
121,379
Cash, Cash Equivalents & STI
25,809
129,936
115,747
Accounts Receivable, Net
1,519
297
166
Inventories
888
1,360
1,042
Total Current Liabilities
19,793
60,454
42,500
Payables & Accruals
- -
- -
- -
ST Debt
13,205
12,409
12,112
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
154.91%
148.28%
Free Cash Flow
- -
54.49%
53.31%
Net Income, GAAP
- -
10.75%
-50.23%
Sales/Revenue/Turnover
- -
100.71%
64.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
97
389
218
1,079
1,783
2025
169
865
832
1,072
2,939
2026
393
176
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
285
-268
-1,183
-562.43
-1,854
2025
-802
323
-440
84.09
-766
2026
225.11
-176.94
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ju-Hee Kim
Full Time Employees
73
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Seongnam-si South Korea
IPO Date
Nov 22, 2022
Website
inventagelab.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Inventage Lab, Inc. is a South Korea-based clinical-stage biotechnology company that develops long-acting injectable therapeutics and advanced genetic medicine delivery systems utilizing proprietary microfluidic formulation platforms. The company operates through two primary technology platforms: IVL-DrugFluidic, a microfluidics-based drug delivery system that engineers uniform, high-encapsulation microspheres for extended-release injectable small molecules and peptides; and IVL-GeneFluidic, a precision manufacturing platform for lipid nanoparticles (LNPs) designed for the stable formulation, encapsulation, and delivery of messenger RNA (mRNA) and other nucleic acid therapeutics. Inventage Lab's core pharmaceutical pipeline and product offerings include IVL3001 and IVL3002, one-month and three-month sustained-release injectable formulations of finasteride and dutasteride for androgenetic alopecia; IVL3003, a long-acting depot formulation of donepezil for Alzheimer's disease and cognitive impairment; IVL3004, an extended-release naltrexone injectable for alcohol and opioid dependence; IVL3005, a sustained-release formulation of glucagon-like peptide-1 (GLP-1) receptor agonists for obesity and type 2 diabetes; and veterinary pharmaceuticals, including long-acting antiparasitic injectables for companion animals. In addition to internal pipeline development, the company provides contract development and manufacturing organization (CDMO) services, microfluidic system engineering, and formulation optimization for global pharmaceutical partners. In recent corporate developments, Inventage Lab has expanded its strategic collaborations and licensing partnerships with major pharmaceutical enterprises, including co-development and commercialization agreements with Daewoong Pharmaceutical and Chong Kun Dang for its long-acting hair loss treatments, alongside research collaborations with Yuhan Corporation. The company has also expanded its therapeutic pipeline into long-acting GLP-1 obesity treatments, progressed international clinical evaluations for its microsphere injectable candidates, and broadened its IVL-GeneFluidic platform into commercial-scale CDMO services to support RNA therapeutics and vaccine developers. Founded in 2015, Inventage Lab, Inc. is headquartered in Seongnam-si, Gyeonggi-do, South Korea.